IN8bio reports 92% of INB-200 patients exceed 7-month PFS in Phase 1 GBM study

IN8BIO, INC.

92% of evaluable patients exceeded median PFS of 7 months (Stupp regimen); median follow-up 11.7 months.
One Cohort 2 patient alive and progression-free at 34.9+ months; IDH-mutant glioma case.
No CRS, ICANS, or dose-limiting toxicities; common AEs were Grade 1-2 related to TMZ.
Phase 2 INB-400 now dosing newly diagnosed GBM patients with up to six infusions.
Radiographic improvements included resolution of midline shift and 36% lesion decrease in one patient.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.